Nifekalant
Chemical compound
Pharmaceutical compound
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H27N5O5 |
Molar mass | 405.455 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.[1] It has the brand name Shinbit.
References
[edit]- ^ Oyabe A, Sano H (February 2002). "Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug". Nippon Yakurigaku Zasshi. 119 (2): 103–9. doi:10.1254/fpj.119.103. PMID 11862758.
Channel blockers |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor agonists and antagonists |
| ||||||||||||
Ion transporters |
| ||||||||||||
|
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |